Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...

Organovo expressed enthusiasm about continuing FXR314’s development in MASH. However, in its announcement with Lilly, the company only mentions its focus on IBD. A Phase II trial in IBD is planned, ...

OliX selected the target after looking at genomic variants linked to MASH and other liver diseases. The Korean biotech is running a phase 1 trial of the candidate in healthy volunteers, and Lilly ...

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other ...

Eli Lilly (NYSE: LLY) stock defied today's market ... colitis and metabolic dysfunction-associated steatohepatitis (MASH). Where to invest $1,000 right now? Our analyst team just revealed what ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

MASH begins with fat buildup on the liver ... but Dr. Aminian has previously consulted for weight-loss drugmaker Eli Lilly and for companies that make equipment used in bariatric surgery.